Mersana Therapeutics to Present at May 2024 Investor Conferences

CAMBRIDGE, Mass., May 22, 2024 — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on creating and advancing a line of antibody-drug conjugates (ADCs) aimed at addressing cancers with significant unmet needs, has announced its participation in upcoming investor conferences.

The company will be featured in two prominent events. Firstly, Mersana's management will partake in a fireside chat format at the TD Cowen 5th Annual Oncology Innovation Summit, scheduled for Wednesday, May 29, 2024, at 9:00 a.m. Eastern Time. Following this, they will present in a similar format at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time. Both events will be accessible via live webcasts on the company's website in the Investors & Media section. Additionally, recordings of these presentations will be available for about 90 days post-event.

Mersana Therapeutics is dedicated to the innovation and development of ADCs, harnessing the potential of these therapies to address various cancer types. The company employs two proprietary platforms: Dolasynthen, a cytotoxic ADC platform, and Immunosynthen, an immunostimulatory ADC platform. These platforms are pivotal in generating both in-house and collaborative product candidates aimed at treating different forms of cancer.

Among Mersana's current pipeline, XMT-1660 and XMT-2056 stand out prominently. XMT-1660 is a Dolasynthen ADC designed to target B7-H4, a protein expressed in certain malignancies. Meanwhile, XMT-2056 is an Immunosynthen ADC targeting a novel epitope of the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some cancer types.

The commitment of Mersana Therapeutics lies in developing pioneering treatment options, driven by the urgent needs of patients seeking new cancer therapies. The company frequently updates its stakeholders and the public, ensuring transparency and accessibility to pertinent information through the Investors & Media section of their website.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!